Neurocrine Biosciences
NBIX
#1374
Rank
S$20.05 B
Marketcap
S$201.10
Share price
-0.33%
Change (1 day)
16.13%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : S$0.55 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is S$0.55 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31S$0.61 B9.33%
2023-12-31S$0.56 B60.53%
2022-12-31S$0.35 B-40.8%
2021-12-31S$0.59 B9.15%
2020-12-31S$0.54 B-18.35%
2019-12-31S$0.66 B25.87%
2018-12-31S$0.53 B7.36%
2017-12-31S$0.49 B
2009-12-31S$16.18 M-26.49%
2008-12-31S$22.01 M929.73%
2007-12-31S$2.13 M-97.4%
2006-12-31S$82.25 M-16.84%
2005-12-31S$98.9 M-8.32%
2004-12-31S$0.10 B74.28%
2003-12-31S$61.89 M349.58%
2002-12-31S$13.76 M30.78%
2001-12-31S$10.52 M56.96%
2000-12-31S$6.7 M29.95%
1999-12-31S$5.16 M4.21%
1998-12-31S$4.95 M83.61%
1997-12-31S$2.69 M20.47%
1996-12-31S$2.23 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
S$0.89 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$11.60 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
S$0.34 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$55.15 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$89.19 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$78.95 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$0.80 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S$24.1 M-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA